Results 81 to 90 of about 15,930 (153)

A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report. [PDF]

Front Oncol
Cha M, Yi H, Li H, Peng R.
europepmc   +1 more source

CDK8/19 inhibition prevents adaptive resistance to CDK4/6 inhibitors in vitro and in vivo. [PDF]

Cell Rep Med
Mack ZT, Yastrebova M, Lim CU, Ding X, Li J, Khamidullina A, Sharko AC, Saint-Antoine M, Hilimire TA, Schools GP, Digsby K, Eckstrom A, Belcher E, Madiot G, Ji H, Sikirzhitski V, Cai C, Cai G, Singh A, Tatarskiy V, Chen M, Roninson IB, Broude EV.   +22 more
europepmc   +1 more source

Neoadjuvant Palbociclib Treatment Impacts Cell Cycle Progression of DCIS. [PDF]

Cancers (Basel)
Battina R, Mainor C, Schmidt MO, Gallanis GT, Sharif GM, Walsh E, Whitaker K, Greenwalt I, Cruz L, Swanson N, Bouker KB, Wellstein A, Isaacs C, Pohlmann PR, Riegel AT.   +14 more
europepmc   +1 more source

Risk factors of hepatotoxicity with ribociclib in hormone receptor-positive breast cancer. [PDF]

J Chin Med Assoc
Lin WC, Chang YL, Wang SF, Hsu CC, Chou CY, Tseng LM, Chao TC.   +6 more
europepmc   +1 more source

Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA. [PDF]

Breast
Liu S, Wang K, Chen H, Wan Z, Dou L, Li S.   +5 more
europepmc   +1 more source

P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer in the USA-A Vodcast. [PDF]

Target Oncol
Rugo HS, Ryan JC.
europepmc   +1 more source

Identification of benzoxazine scaffold derivatives as novel CDK4 inhibitors for the treatment of cancer. [PDF]

J Enzyme Inhib Med Chem
Lin C, Sun S, Zhang H, Yang D, Wei Y, Li B.   +5 more
europepmc   +1 more source

LC-MS/MS-based clinical value exploration of the methionine cycle in luminal breast cancer. [PDF]

Oncol Lett
Wu W, Tu Y, Yao H, Mao Y, Mao C, Xu F, Wang Z.   +6 more
europepmc   +1 more source

Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway. [PDF]

Drug Des Devel Ther
Zhu L, Yang J, Li F, Wang D, Zhang W, Zhang J, Duan Z, Hu Y, Zhou Y.   +8 more
europepmc   +1 more source

Molecular signatures of triple-negative breast cancer cells acquiring palbociclib resistance via continuous exposure. [PDF]

Oncol Lett
Enomoto D, Iwasa Y, Irie N, Ohata H, Uemichi Y, Mabuchi M, Shimizu T, Takara K.   +7 more
europepmc   +1 more source